Skip to content

Study · Randomized controlled trial · n = 25 · 2016

11 results

Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.

Kuppens RJ, Donze SH, Hokken-Koelega AC

Clinical endocrinology26 Aug 2016Cited by 68 (Europe PMC)

PMID27486141 (opens in a new tab)DOI10.1111/cen.13169 (opens in a new tab)PepBankPUB-27486141
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome, intranasal oxytocin had no significant effect on social behaviour in the total group versus placebo.

    In plain wordsIn children with Prader-Willi syndrome, nasal oxytocin did not change social behaviour in the whole group compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSocial behaviour in the total group
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    In the total group, no significant effects of oxytocin on social behaviour or hyperphagia were found
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome, intranasal oxytocin had no significant effect on hyperphagia in the total group versus placebo.

    In plain wordsIn children with Prader-Willi syndrome, nasal oxytocin did not change excessive eating in the whole group compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeHyperphagia in the total group
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    In the total group, no significant effects of oxytocin on social behaviour or hyperphagia were found
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  3. 03HumanRandomized controlled trialSafety outcome

    In children with Prader-Willi syndrome, no side effects or adverse events occurred during intranasal oxytocin treatment.

    In plain wordsIn children with Prader-Willi syndrome, no side effects or adverse events were reported with nasal oxytocin.

    Peptide
    Oxytocin
    Outcome
    No significant changeSide effects and adverse events
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no side effects or adverse events.
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome younger than 11 years, parents reported significantly less anger during oxytocin than during placebo.

    In plain wordsIn children with Prader-Willi syndrome under 11, parents reported less anger during nasal oxytocin than during placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseAnger in children younger than 11 years
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    in the 17 children younger than 11 years, parents reported significantly less anger (P = 0·001)
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome younger than 11 years, parents reported significantly less sadness during oxytocin than during placebo.

    In plain wordsIn children with Prader-Willi syndrome under 11, parents reported less sadness during nasal oxytocin than during placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseSadness in children younger than 11 years
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    in the 17 children younger than 11 years, parents reported significantly less anger (P = 0·001), sadness (P = 0·005)
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome younger than 11 years, parents reported significantly fewer conflicts during oxytocin than during placebo.

    In plain wordsIn children with Prader-Willi syndrome under 11, parents reported fewer conflicts during nasal oxytocin than during placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseConflicts in children younger than 11 years
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    in the 17 children younger than 11 years, parents reported significantly less anger (P = 0·001), sadness (P = 0·005), conflicts (P = 0·010)
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome younger than 11 years, parents reported significantly less food-related behaviour during oxytocin than during placebo.

    In plain wordsIn children with Prader-Willi syndrome under 11, parents reported less food-related behaviour during nasal oxytocin than during placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseFood-related behaviour in children younger than 11 years
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    in the 17 children younger than 11 years, parents reported significantly less anger (P = 0·001), sadness (P = 0·005), conflicts (P = 0·010) and food-related behaviour (P = 0·011)
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome younger than 11 years, parents reported significant improvement of social behaviour during oxytocin versus placebo.

    In plain wordsIn children with Prader-Willi syndrome under 11, parents reported better social behaviour during nasal oxytocin than during placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseSocial behaviour in children younger than 11 years
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    in the 17 children younger than 11 years, parents reported significantly less anger (P = 0·001), sadness (P = 0·005), conflicts (P = 0·010) and food-related behaviour (P = 0·011), and improvement of social behaviour (P = 0·018)
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  9. 09HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome older than 11 years, the item happiness was negatively influenced by oxytocin compared with placebo.

    In plain wordsIn children with Prader-Willi syndrome over 11, happiness was affected negatively by nasal oxytocin compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseHappiness in children older than 11 years
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    In the eight children older than 11 years, the items happiness (P = 0·039)
    2 context sentences
    Summary · context
    negatively influenced by oxytocin treatment compared to placebo.
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  10. 10HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome older than 11 years, the item anger was negatively influenced by oxytocin compared with placebo.

    In plain wordsIn children with Prader-Willi syndrome over 11, anger was affected negatively by nasal oxytocin compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedAnger in children older than 11 years
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    In the eight children older than 11 years, the items happiness (P = 0·039), anger (P = 0·042) and sadness (P = 0·042) were negatively influenced by oxytocin treatment compared to placebo.
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).
  11. 11HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome older than 11 years, the item sadness was negatively influenced by oxytocin compared with placebo.

    In plain wordsIn children with Prader-Willi syndrome over 11, sadness was affected negatively by nasal oxytocin compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedSadness in children older than 11 years
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24-48 IU/day · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    In the eight children older than 11 years, the items happiness (P = 0·039), anger (P = 0·042) and sadness (P = 0·042) were negatively influenced by oxytocin treatment compared to placebo.
    1 context sentence
    Summary · context
    Crossover intervention with twice daily intranasal oxytocin (dose range 24-48 IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 6 to 14 years).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.